Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions Reka E. PatakyStirling BryanDean A. Regier Scoping Review 27 July 2022 Pages: 931 - 941
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review Suzana KarimBenjamin M. CraigCatharina G. M. Groothuis-Oudshoorn Systematic Review 12 August 2022 Pages: 943 - 956
China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population Jing WuXiaoning Hefor the CHROME Study Group Original Research Article 18 July 2022 Pages: 957 - 969
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience Mary BunkaShahzad GhanbarianStirling Bryan Original Research Article Open access 25 July 2022 Pages: 971 - 977
Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA Jing Voon ChenJames C. GahnPaul N. Mudd, Jr. Original Research Article Open access 26 July 2022 Pages: 979 - 988
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations Ka Keat LimRositsa Koleva-KolarovaJulia Fox-Rushby Original Research Article 30 July 2022 Pages: 989 - 1003
Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network Stephanie HarvardAmin AdibiMohsen Sadatsafavi Research Letter 30 July 2022 Pages: 1005 - 1009
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine” Nikolaos GiannelosMarie Libérée NishimweNicolas Lecrenier Letter to the Editor Open access 26 September 2022 Pages: 1011 - 1012
Authors’ Reply to Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine” Joke BilckePhilippe Beutels Letter to the Editor 26 September 2022 Pages: 1013 - 1014